High choroidal neovascularization reactivation rates seen after anti-VEGF discontinuation

Posted on

High choroidal neovascularization (CNV) recurrence rates after anti-VEGF treatment is discontinued supports the need for the development of a rational discontinuation strategy, according to a study.

In this prospective, single-center clinical trial, 157 patients with age-related macular degeneration (AMD) were randomly assigned to receive intravitreal bevacizumab injections every 4, 6, or 8 weeks for 1 year. At the end of 1-year of treatment, CNV activity was found in 42% (n = 66) of patients. Within the first year after discontinuation of treatment, 61 of the remaining 91 patients needed retreatment for active CNV. Of those 61 patients, 50 experienced CNV reactivation within 6 months of their final treatment for CNV.


Amarakoon S, Martinez-Ciriano JP, Baarsma S, et al. Reactivation of CNV after discontinuation of bevacizumab treatment of age-related macular degeneration. Ophthalmologica. 2021; https://doi.org/10.1159/000514539

Related Articles
Wearable collision warning device helps visually impaired individuals
Jul 22, 2021
Psoriasis linked with significantly higher risk of retinal diseases
Jul 20, 2021
Ranibizumab biosimilar has comparable efficacy, safety profile to reference product in patients with nAMD
Jul 19, 2021